
Sign up to save your podcasts
Or


Jennifer Quint, Thorax’s Journal Club editor, talks to David Jablons, University of California San Francisco, and consultant for Life Technologies, about his assay to predict survival in resected non-squamous, non-small-cell lung cancer.
See also:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961941-7/abstract
By BMJ Group4
11 ratings
Jennifer Quint, Thorax’s Journal Club editor, talks to David Jablons, University of California San Francisco, and consultant for Life Technologies, about his assay to predict survival in resected non-squamous, non-small-cell lung cancer.
See also:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961941-7/abstract

138 Listeners

498 Listeners

37 Listeners

52 Listeners

63 Listeners

5 Listeners

8 Listeners

5 Listeners

3 Listeners

3 Listeners

37 Listeners

5 Listeners

8 Listeners

38 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

36 Listeners

14 Listeners

3 Listeners

3 Listeners

25 Listeners

1,154 Listeners

194 Listeners

513 Listeners

24 Listeners

9 Listeners

370 Listeners

56 Listeners

233 Listeners